Seven key publications: pathogenicity, diagnostics, resistance, treatment, maxillofacial disease, and ABPA in COPD.

---

1. Comparative Overview of A. fumigatus, A. flavus, and A. niger

Rafique et al., J Infect Public Health, 2025
DOI: 10.1016/j.jiph.2025.103070

What this adds

• A major comparative review (2000–2025) of the three most clinically relevant Aspergillus species.

• Highlights broad clinical spectrum: allergy → chronic disease → invasive aspergillosis.

• Identifies species-specific concerns:

  • A. fumigatus: globally dominant, rapidly evolving triazole resistance.

  • A. flavus: important in warmer climates; high aflatoxin relevance.

  • A. niger: relatively lower virulence but significant in sinus disease.

• Public health message: surveillance gaps persist, especially for non-fumigatus species.

Why it matters

A strong reference paper supporting the WHO prioritisation of Aspergillus, and reinforcing the need for:

• Better diagnostics

• Species-level identification

• Environmental resistance monitoring

---

2. GFP Fusion Protein Proteolysis in A. fumigatus

Paul & Moye-Rowley, G3 (Bethesda), 2025
DOI: 10.1093/g3journal/jkaf295

What this adds

• Fundamental molecular biology study revealing regulated degradation pathways of green fluorescent protein (GFP) fusion proteins inside A. fumigatus.

• Demonstrates how the fungus controls protein turnover under stress conditions.

Why it matters

• Advances tools for fungal cell biology.

• Supports drug development by clarifying pathways involved in stress response and antifungal tolerance.

• Reinforces WHO’s classification of A. fumigatus as one of the four most critical fungi to study.

---

3. ABPA in COPD: Case Series + Review

Ren et al., BMC Pulmonary Medicine, 2025
DOI: 10.1186/s12890-025-04027-8

What this adds

• 11 COPD cases with confirmed Allergic Bronchopulmonary Aspergillosis — highlighting:

  • Under-recognition in COPD

  • Overlap with chronic bronchitis/bronchiectasis symptoms

  • Frequent misdiagnosis as recurrent infections or COPD exacerbations

• Provides diagnostic guidance and a literature synthesis.

Why it matters

• Significant implications for case finding across the UK.

• Supports NAC messaging: ABPA is not only an asthma disease.

• Reinforces need for:

  • IgE/IgG screening

  • Early CT imaging

  • Awareness among COPD teams and primary care

---

4. EL219: Next-Generation Polyene Antifungal

Youssef et al., AAC, 2025
DOI: 10.1128/aac.01400-25

What this adds

• Animal model evidence that EL219, a modern polyene, is effective against:

  • Triazole-susceptible A. fumigatus

  • Azole-resistant isolates

  • Difficult species (A. lentulus, A. calidoustus)

Why it matters

• Highly relevant to rising global antifungal resistance.

• Early indication that EL219 may fill a clinical gap similar to (or complementary to) olorofim and fosmanogepix.

• Suggests strong activity even in immunosuppressed models.

---

5. Misidentification & Triazole Resistance in Aspergillus tubingensis

Wang et al., JAMA Network Open, 2025
DOI: 10.1001/jamanetworkopen.2025.43630

What this adds

• Large Southern California population study showing:

  • Frequent misidentification of A. tubingensis as A. niger.

  • Notable azole resistance rates in correctly identified isolates.

• Stresses need for genomic sequencing or MALDI-TOF with updated libraries.

Why it matters

• Strong evidence that misidentification leads to:

  • Inappropriate antifungal therapy

  • Poor outcomes

• Supports calls for expanded diagnostic reference services such as MRCM.

---

6. 50-Year Review of Oral Fungal Infections in Thailand

Kosanwat et al., Clinical Oral Investigations, 2025
DOI: 10.1007/s00784-025-06685-8

What this adds

• Longitudinal study: 29% of deep infections involved aspergillosis.

• Mean age 62 → older adults most affected.

• Many cases were mucormycosis, histoplasmosis, or aspergillosis presenting late.

Why it matters

• Shows that oral/maxillofacial fungal disease remains under-recognised globally.

• Relevant to dental teams → better imaging + biopsy protocols needed.

• May help NAC/CARES identify referral pathways from dental medicine.

---

7. Management of Maxillary Sinus Aspergillosis with Implants

Khoury et al., Int J Oral Implantol, 2025

What this adds

• Real-world 3–10 year follow-up of 11 patients.

• Standardised approach:

  • Surgical clearance

  • Antifungal therapy

  • Successful implant-prosthetic rehabilitation

Why it matters

• Demonstrates excellent long-term outcomes when sinus aspergillosis is properly treated.

• Practical implications for:

  • ENT surgeons

  • Oral surgeons

  • Implant dentistry

• Supports inclusion of aspergillosis in sinus disease differential diagnosis.

---

Cross-Cutting Themes Emerging This Week

1. Under-recognition and misidentification

• ABPA in COPD

• Misidentified A. tubingensis

• Asymptomatic sinus disease

• Oral/maxillofacial deep fungal infections

→ Key NAC message: We are missing cases in primary care, COPD clinics, ENT, and dentistry.

---

2. Antifungal resistance remains a central threat

• Contemporary reviews of species-specific resistance patterns

• EL219’s promise against resistant species

• Misidentification leading to incorrect susceptibility assumptions

---

3. Need for better diagnostics and reference centres

• Species-level identification is essential

• Supports arguments for expansion of MRCM-style national services

---

4. The clinical spectrum is broad

From allergy (ABPA in COPD) → chronic sinus disease → deep oral infections → invasive pulmonary aspergillosis.
This reinforces the message: aspergillosis is multi-specialty, not confined to respiratory medicine.

---

Weekly NAC/MRCM Take-Home Messages

• COPD teams should screen for ABPA more frequently—especially in patients with recurrent “infective exacerbations.”

• Species-level identification is increasingly important; misidentification contributes to treatment failure.

• New antifungals like EL219 show promise against resistant strains including A. lentulus.

• Dental and ENT teams need better awareness: sinus and oral fungal infections remain overlooked but treatable.

• Global reviews show growing public health significance of Aspergillus species—aligning with WHO priorities.

Path: Start » Weekly Updates » Aspergillosis Research Highlights — Week in Review (Last 7 Days: Week 50)